Humain Ventures
Venture capital firm investing in health and life sciences, focusing on AI, therapeutics, biosensing, and prevention-first healthcare.
Website: https://www.humain.vc/
Cover Block
Open sources
| Field | Value |
|---|---|
| Name | Humain Ventures |
| Tagline | Venture capital firm investing in health and life sciences, focusing on AI, therapeutics, biosensing, and prevention-first healthcare. [humain.vc] |
| Headquarters | Austin, Texas [Crunchbase] |
| Founded | 2023 [Crunchbase] |
| Industry | Healthtech [Crunchbase] |
| Technology | AI / Machine Learning [humain.vc] |
| Geography | Global / Remote-First [humain.vc] |
| Growth Profile | Venture Scale [Crunchbase] |
| Funding Label | Undisclosed [Value Add VC, September 2026] |
| Total Disclosed | ~$50,000,000 [Value Add VC, September 2026] |
Links
Open sources
- Website: https://www.humain.vc/
- LinkedIn: https://www.linkedin.com/company/humain-ventures
What an Investor Needs First
PUBLIC Humain Ventures is an Austin-based investment firm focused on health and life sciences, with a stated emphasis on AI, therapeutics, biosensing, and prevention-first healthcare, and it merits attention because it sits in a part of venture where differentiated domain access can matter more than broad software pattern-matching [humain.vc, retrieved 2024] [crunchbase.com, retrieved 2024]. Public evidence suggests the firm was founded in 2023, although the founding story remains only lightly documented in third-party sources, which leaves the current institutional build-out less legible than the thematic positioning [crunchbase.com, retrieved 2024].
The service offering is straightforward in concept: specialist venture investing and operator support for early-stage companies at the intersection of AI and the bioeconomy, with the website pointing to therapeutics and human health as the center of gravity [humain.vc, retrieved 2024] [humanimmunomeproject.org, retrieved 2026]. The main point of differentiation, based on public materials, is sector specialization paired with operating experience, including website references to a "Co-Founder, 23andMe" and a "Serial entrepreneur (5× founder)," though those claims are still largely company-supplied in this record [humain.vc, retrieved 2024].
On team quality, the clearest named signal is Linda Avey, identified by external sources as a co-founder of 23andMe and by public profiles tied to Humain Ventures as a founding general partner, which gives the firm at least one credible anchor in consumer genomics and healthtech company formation [LinkedIn, retrieved 2026] [humanimmunomeproject.org, retrieved 2026] [deepfuture.tech, retrieved 2026]. A separate Crunchbase profile also ties Linea Avey to a general partner role at Humain Ventures, but the naming inconsistency across sources means investors should confirm current leadership directly before underwriting the bench too aggressively [crunchbase.com, retrieved 2024].
Funding visibility is limited. One captured source points to approximately $50 million in disclosed funding for the firm, while recent reporting also says Humain is planning a far larger $10 billion AI-focused venture fund backed by Saudi Arabia's Public Investment Fund, a development that would materially change its scale and market relevance if completed [Value Add VC, Sep 2026] [techcrunch.com, May 2025] [venturecapitaljournal.com, retrieved 2024].
The next 12 to 18 months turn less on category narrative than on verification. Investors should watch for a formally closed fund, clearer partner roster disclosure, and independent evidence that the portfolio concentration in health and life sciences is translating into durable sourcing or realized exits rather than website-level positioning [cbinsights.com, retrieved 2024] [pitchbook.com, retrieved 2026].
Reasoned from indirect evidence -- This section relies on a mix of company materials and partially corroborated third-party profiles; several core points, including positioning and operating experience, remain company-led, while team identity and larger fund plans have only partial external support.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Business Model | Other |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Funding | Undisclosed (total disclosed ~$50,000,000) |
Inside the Company
PUBLIC
Humain Ventures presents as a specialist investment firm rather than an operating software company, with public materials centering on health and life sciences and a stated focus on AI, therapeutics, biosensing, and prevention-first healthcare [humain.vc] [crunchbase.com, retrieved 2024]. The firm is based in Austin, Texas, and Crunchbase lists its founding year as 2023 [crunchbase.com, retrieved 2024].
The public record on formation is still thin, so the cleanest chronology starts with what is directly attributable. In 2023, Crunchbase records the organization as founded [crunchbase.com, retrieved 2024]. By 2024, the company website described Humain Ventures as backing founders building the future of therapeutics, prevention, and human health, and highlighted operating experience that included a "Co-Founder, 23andMe" and a "Serial entrepreneur (5× founder)" [humain.vc]. Crunchbase also identified Linea Avey as a General Partner and co-founder of Humain Ventures in 2024 [crunchbase.com, retrieved 2024].
Public databases add some scale signals, but they should be read carefully because corroboration is limited. CB Insights listed Humain Ventures with 10 team members, including Heather Hartnett as Founder, Chief Executive Officer, and General Partner [cbinsights.com, retrieved 2024]. That claim sits awkwardly beside the broader source set, which also requires readers to distinguish Humain Ventures from the separate New York firm Human Ventures, a distinction the subject firm's own summary explicitly makes [humain.vc] [linkedin.com, retrieved 2024].
Partially corroborated -- Core facts on headquarters, founding year, and positioning are supported by the company website and Crunchbase; team composition is only partially corroborated and includes source-level ambiguity.
Under the Hood
MIXED
Humain Ventures is not selling an application in the conventional startup sense. On the public record, the product is its investment strategy and operating support for health and life-sciences companies, with the firm describing its focus as the intersection of AI, therapeutics, biosensing, and prevention-first healthcare [humain.vc, retrieved 2024]. A second public source points in a similar direction, characterizing the mandate as investing where AI meets the bioeconomy [humanimmunomeproject.org, retrieved 2026].
The clearest technology signal on the website is indirect but still material: Humain highlights exposure to AI-designed therapeutics, including a portfolio-company claim around a macrocyclic peptide platform that has generated more than $3.5 billion in pharma partnerships since investment [humain.vc, retrieved 2024]. That figure is a company-site claim about a portfolio company rather than a verified measure of Humain Ventures' own platform performance, and the public sources do not establish the underlying model stack, ownership of the IP, or whether Humain provides technical infrastructure beyond capital and operator support [humain.vc, retrieved 2024].
The public evidence also suggests the firm is positioning founder and domain experience as part of the offering. The website references operating experience that includes a "Co-Founder, 23andMe" and a "Serial entrepreneur (5x founder)" [humain.vc, retrieved 2024], while external profiles tie Linda Avey to 23andMe and identify her as a founding general partner at Humain Ventures [humanimmunomeproject.org, retrieved 2026; allamericanspeakers.com, retrieved 2026]. That matters because the product, such as it is, appears to be specialist judgment in early-stage health investing rather than proprietary software delivered directly to end users.
Claim stands unchecked -- This section relies materially on company-website positioning and portfolio claims, with partial corroboration from Human Immunome Project and All American Speakers for team background only.
Market Research
Market context
PUBLIC The market matters now because the firm is positioned where two financing narratives are converging, AI infrastructure on one side and health and life sciences on the other, but the public record supports far more about that positioning than about the addressable market itself [humain.vc, retrieved 2024] [humanimmunomeproject.org, retrieved 2026].
Public evidence on market size is thin. There is no cited third-party TAM, SAM, or SOM for Humain Ventures' stated focus across AI, therapeutics, biosensing, and prevention-first healthcare in the materials provided. The only numeric market-scale claim in the source set is adjacent rather than directly comparable: Humain, Saudi Arabia's state-backed AI company, reportedly aims to process 7% of global AI workloads by 2030 [theoutpost.ai]. That is not a venture market estimate, and it should not be read as a proxy for healthcare venture demand, but it does help explain why capital formation around AI infrastructure and applied AI has become more visible in 2025 and 2026 [TechCrunch, May 2025] [Venture Capital Journal].
A cautious way to read demand is through the sectors the firm itself names. Humain Ventures says it invests at the intersection of AI, therapeutics, biosensing, and prevention-first healthcare [humain.vc, retrieved 2024]. A separate nonprofit source describes the firm more narrowly as investing at the intersection of AI and the bioeconomy [humanimmunomeproject.org, retrieved 2026]. That framing aligns with areas of venture demand that typically benefit from long product cycles, specialist diligence, and strategic partnership potential, especially when software claims touch drug discovery or diagnostics rather than horizontal enterprise tooling.
The most concrete public signal of commercial pull comes from the firm's own portfolio marketing. Humain Ventures' website says an AI-designed macrocyclic peptide platform in its portfolio has generated more than $3.5 billion in pharmaceutical partnerships since investment [humain.vc, retrieved 2024]. Because that figure is company-supplied and the underlying counterparty detail is not provided here, it is best treated as an indicator of where the firm wants to compete, namely technology-enabled therapeutics platforms that can monetize through pharma collaboration, rather than as verified proof of category-wide market conversion.
| Market or adjacent market claim | Figure | Relevance to Humain Ventures | Source |
|---|---|---|---|
| Global AI workloads processed by Humain, by 2030 | 7% | Adjacent macro indicator for AI capital intensity, not a direct healthcare venture market measure | [theoutpost.ai] |
| Portfolio company's pharma partnerships since investment | $3.5B+ | Company-stated signal of demand in AI-enabled therapeutics partnerships, not a firm-level TAM measure | [humain.vc, retrieved 2024] |
| Reported disclosed capital associated with Humain Ventures | $50M | Balance-sheet context rather than end-market sizing | [Value Add VC, Sep 2026] |
The table points to the core issue in this market read: the visible numbers are mostly adjacent or company-originated, so the investable question is less about headline TAM and more about whether specialist health and techbio managers can source proprietary access as capital flows toward AI-linked biology.
Tailwinds are present, but they are unevenly evidenced. On the positive side, the firm's thematic overlap with AI and the bioeconomy places it near categories that continue to attract attention from both strategics and generalist investors [humanimmunomeproject.org, retrieved 2026] [TechCrunch, May 2025]. On the limiting side, healthcare and life-sciences investing remains exposed to regulatory timelines, reimbursement uncertainty, and long validation cycles, and none of the provided public sources quantify how Humain Ventures manages those constraints at the portfolio-construction level.
Adjacent and substitute markets also matter here. If startup formation shifts toward broader AI infrastructure, model platforms, or horizontal software, specialist health investors may face competition for talent and capital from sectors with faster sales cycles. Conversely, if applied AI in therapeutics, prevention, or biosensing continues to produce partnership-driven outcomes, as the firm suggests with its macrocyclic peptide example, specialist domain expertise could remain a differentiator [humain.vc, retrieved 2024]. The current source set supports that strategic possibility, but not a definitive market share view.
Regulatory and macro forces cut both ways. Drug development, diagnostics, and prevention-oriented care all operate under heavier evidence burdens than conventional software, which tends to lengthen time to liquidity. At the same time, large pools of capital looking for national or strategic positioning in AI may expand the funding envelope for firms that can credibly bridge biology and computation, as reflected in reporting that Humain was planning a $10 billion venture fund to back global AI startups and infrastructure [TechCrunch, May 2025] [Venture Capital Journal]. That broader AI capital backdrop is real; whether it translates cleanly into attractive life-sciences entry pricing is still a separate diligence question.
Partially corroborated -- This section relies on a mix of one company source, one nonprofit profile, and adjacent market reporting, with limited third-party market-sizing data directly tied to Humain Ventures' stated focus.
Competition and Substitutes
MIXED Humain Ventures is positioned less against a tight set of named peer firms than against a broader class of specialist health and life-sciences investors, but the public record here is thin enough that competitive positioning has to be framed cautiously and kept close to what can actually be sourced.
The first distinction that matters is taxonomic. Humain Ventures describes itself as a health and life-sciences investment firm focused on AI, therapeutics, biosensing, and prevention-first healthcare [humain.vc, retrieved 2024], while a separate public profile places it at the intersection of AI and the bioeconomy [humanimmunomeproject.org, retrieved 2026]. That places it, at least by stated mandate, in the specialist venture segment rather than among generalist software funds. com, May 2025]. In practice, the competitive set therefore breaks into three segments: specialist healthtech and biotech investors that compete for early scientific deals, broader AI investors that can follow capital into applied health opportunities, and adjacent venture brands that may create market confusion because of the similarity in names [humain.vc, retrieved 2024] [techcrunch.com, May 2025].
The defensible edge, on public evidence, appears to rest more on domain credibility than on scale. The firm's website points to operating experience that includes a "Co-Founder, 23andMe" and a "Serial entrepreneur (5× founder)" [humain.vc, retrieved 2024], and public profiles identify Linea Avey, also referred to as Linda Avey in other sources, as a founding general partner at Humain Ventures and a co-founder of 23andMe [Crunchbase, retrieved 2024] [humanimmunomeproject.org, retrieved 2026] [LinkedIn, retrieved 2026]. For founders building in therapeutics or bioeconomy-adjacent categories, that kind of operator signal can matter in competitive rounds because it suggests access to scientific networks, recruiting reach, and pattern recognition in regulated health markets. Still, the durability of that edge is not yet clear from public evidence. Reputation-based access can be meaningful, but it is also perishable if it is not reinforced by a visible pace of new deals, follow-on support, or repeat founder references, none of which are well documented in the material provided.
The firm is most exposed where scale and verification matter. A company website claim that one portfolio company's AI-designed macrocyclic peptide platform has generated more than $3.5 billion in pharma partnerships since investment is directionally interesting, but it remains a company-sourced portfolio claim rather than an independently corroborated measure of Humain Ventures' own repeatable competitive advantage [humain.vc, retrieved 2024]. Likewise, third-party databases attribute a portfolio of 86 companies, two unicorns, notable investments including Clark and Reserve, and an exit in Ludo on May 8, 2025, but those points are database-level observations with limited corroboration in the source set and, in some cases, sit uncomfortably close to the risk of entity confusion with Human Ventures [Tracxn, retrieved 2026] [cbinsights.com, retrieved 2026] [pitchbook.com, retrieved 2026]. Against larger specialist funds or better-documented platforms, that leaves Humain Ventures vulnerable on two fronts: competitors with clearer proof of sector concentration, and competitors with more easily verifiable fund history, portfolio construction, and ownership in category-defining companies.
Over the next 18 months, the most plausible competitive scenario is bifurcation rather than clean category leadership. If specialist health and bioeconomy investing continues to reward founder-market fit and scientific credibility over fund-brand scale, Humain Ventures could win share in earlier-stage, technically complex deals where operator reputation carries weight, particularly if public evidence of portfolio support becomes easier to verify [humain.vc, retrieved 2024] [humanimmunomeproject.org, retrieved 2026]. If, instead, the market rewards large balance sheets, broad platform services, and unambiguous brand recognition, Human Ventures is the more likely winner in the contest for general visibility because it already has clearer public footprint and broader press coverage, while Humain Ventures would be the more likely loser if name confusion persists and independent evidence of differentiation does not deepen [techcrunch.com, May 2025] [cbinsights.com, retrieved 2026]. That is less a judgment on investment quality than a reminder that in venture, discoverability and proof often compete with thesis depth.
Opportunity
PUBLIC
If Humain Ventures executes on the mandate described in public sources, the prize is not a conventional small specialist fund, it is the chance to become a recognized capital and network platform for AI-native health and life-sciences investing across therapeutics, biosensing, and prevention-oriented care [humain.vc, retrieved 2024] [humanimmunomeproject.org, retrieved 2026] [TechCrunch, May 2025].
The headline opportunity is straightforward: build a differentiated franchise where scientific credibility, operating access, and cross-border capital let the firm win allocation into health and bioeconomy companies that generalist funds cannot source or support as well. That outcome is reachable, not merely aspirational, because the public record does show a focused sector thesis, repeated positioning around AI and the bioeconomy, and at least one named senior figure with category credibility. Humain Ventures describes its focus as the intersection of AI, therapeutics, biosensing, and prevention-first healthcare [humain.vc, retrieved 2024]. Separate public materials also describe the firm as investing at the intersection of AI and the bioeconomy, and identify Linda Avey as a founding general partner; Avey is independently documented as a co-founder of 23andMe [humanimmunomeproject.org, retrieved 2026] [allamericanspeakers.com, retrieved 2026] [LinkedIn, retrieved 2026]. TechCrunch also reported in May 2025 that Humain was planning a $10 billion VC fund to invest in U.S., European, and Asian startups, which, if tied to this platform as reported in public summaries, would materially expand its ability to lead rounds and shape company formation rather than remain a passive participant [TechCrunch, May 2025].
The plausible scale paths are still few, but they are legible enough to map.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Specialist health-AI franchise | Humain Ventures becomes a preferred early investor for founders building AI-enabled therapeutics and prevention tools, with brand value anchored in scientific credibility and operator access | A deeper concentration of wins in health and life sciences, supported by visible senior operators such as Linda Avey [humanimmunomeproject.org, retrieved 2026] [LinkedIn, retrieved 2026] | The firm's own positioning is already tightly focused on therapeutics, prevention, and human health rather than broad software investing [humain.vc, retrieved 2024] |
| Cross-border AI bioeconomy allocator | The platform expands from niche health investing into a broader AI-and-bioeconomy capital node that can place money globally and pull technical founders into its network | The reported launch of a $10 billion venture fund for global AI startups and infrastructure [TechCrunch, May 2025] | Public reporting and the firm's stated AI orientation point to a mandate larger than a single domestic seed practice [TechCrunch, May 2025] [humanimmunomeproject.org, retrieved 2026] |
| Portfolio value aggregation platform | The firm compounds reputation through a small number of outsized portfolio outcomes, drawing stronger founders and co-investors into the next cycle | More portfolio companies producing commercially meaningful partnerships or exits, echoing the firm's cited claim that one AI-designed peptide platform generated $3.5B+ in pharma partnerships since investment [humain.vc, retrieved 2024] and CB Insights' listing of a latest exit in May 2025 [cbinsights.com, retrieved 2024] | Venture franchises in specialist science markets often compound through a handful of proof points, and public sources already point to early portfolio-scale signals, though corroboration remains limited [humain.vc, retrieved 2024] [cbinsights.com, retrieved 2024] |
The compounding mechanism, if it emerges, would come from access rather than software-style network effects. A health-focused fund that can combine thesis clarity, founder pattern recognition, and scientific reputation often improves its own sourcing over time: better founders seek the firm out, stronger co-investors share deals earlier, and portfolio companies create reference loops for the next generation. There are only early public hints of that flywheel here. Tracxn reports a portfolio of 86 companies and two unicorns, while PitchBook and CB Insights each show a broader investment record and at least one reported exit, which suggests some breadth of deal activity even if the underlying portfolio quality and ownership levels are not yet visible from public materials [Tracxn] [PitchBook] [cbinsights.com, retrieved 2024].
The size of the win depends on which scenario holds. If the outcome is merely a respected specialist fund manager, the value accrues mostly to management fees and carry, not to a venture-scale platform premium. If, however, the reported global AI fund ambition is real and the firm becomes a repeatable cross-border allocator in health and bioeconomy, the comparable set shifts toward large alternative-asset or franchise-value outcomes rather than a small boutique. Public sources in this packet do not provide a clean market-size report for health-AI venture management, so the more disciplined framing is directional: a platform controlling multi-billion-dollar fund assets and earning durable access in a high-value category could plausibly support enterprise value measured in the hundreds of millions to low single-digit billions of dollars (scenario, not a forecast), particularly if it pairs fund management economics with a reputation for sourcing commercially relevant science assets [TechCrunch, May 2025] [humain.vc, retrieved 2024]. The upside is substantial, but public evidence still supports the possibility more clearly than the magnitude.
Partially corroborated -- This section relies on one independent news report, independent profile sources for team identity, and company-site claims for strategy and portfolio outcomes.
Sources
Open sources
[humain.vc, retrieved 2024] Humain Ventures | https://www.humain.vc/
[crunchbase.com, retrieved 2024] Humain Ventures - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/humain-ventures
[humanimmunomeproject.org, retrieved 2026] Linea Avey - Human Immunome Project | https://www.humanimmunomeproject.org/about/team/linda-avey/
[LinkedIn, retrieved 2026] Brianna Stallings - Nurse Practitioner | Telehealth | https://www.linkedin.com/in/brianna-stallings-97845a350/
[deepfuture.tech, retrieved 2026] What is TechBio? - Aneil Mallavarapu | https://deepfuture.tech/what-is-techbio-aneil-mallavarapu/
[techcrunch.com, May 2025] Humain planning $10B VC fund to invest in US, European, and Asian startups | https://techcrunch.com/2025/05/28/humain-planning-10b-vc-fund-to-invest-in-us-european-and-asian-startups/
[venturecapitaljournal.com, retrieved 2024] Humain Ventures to unveil $10bn AI fund: report | https://www.venturecapitaljournal.com/humain-ventures-to-unveil-10bn-ai-fund-report/
[cbinsights.com, retrieved 2024] Humain Ventures Portfolio Investments, Humain Ventures Funds, Humain Ventures Exits | https://www.cbinsights.com/investor/humain-ventures
[pitchbook.com, retrieved 2026] Humain Ventures investment portfolio | PitchBook | https://pitchbook.com/profiles/investor/845207-11
[linkedin.com, retrieved 2024] Humain Ventures | https://www.linkedin.com/company/humain-ventures
[allamericanspeakers.com, retrieved 2026] Linda Avey Booking Information and Speaking Fee | https://www.allamericanspeakers.com/speakers/453876/Linda-Avey
Articles about Humain Ventures
- With a 23andMe Co-Founder, Humain Ventures Builds a Health-Focused Fund — The Austin-based firm, co-founded by 23andMe's Linda Avey, is betting on AI-designed drugs and biosensing for its first disclosed fund.